NCT02756637View on ClinicalTrials.gov

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

CompletedOBSERVATIONAL
Enrollment

634

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Bladder Cancer
Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02756637 - Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710 | Biotech Hunter | Biotech Hunter